AAVLife Raises $12M in Series A Financing
Summary
AAVLife, a Paris, France-based gene-therapy company focusing on rare diseases, raised $12m in Series A financing.Led by Amber Salzman, Ph.D., co-founder and Chief Executive Officer, AAVLife has already advanced research of a gene-therapy approach into further preclinical studies to inform decisions about dosing and route of administration to be used in a clinical trial.The goal is to start a clinical trial in 2015 to evaluate gene therapy for the cardiac dysfunction associated with Friedreich’s ataxia, which affects 10,000 to 20,000 people in the United States and Europe.– Pierre Bougnères, M.D., Ph.D., Head of Pediatric Endocrinology at Hôpital Bicêtre Paris Sud.– Hélène Puccio, Ph.D., Head of a research team at the Institute of Genetics and Molecular and Cellular Biology, University of Strasbourg, France.